NASDAQ:RNTX Rein Therapeutics (RNTX) Stock Price, News & Analysis $1.19 +0.06 (+5.52%) As of 10:05 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Rein Therapeutics Stock (NASDAQ:RNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rein Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.1950-Day Range$1.10▼$1.8852-Week Range$1.04▼$4.40Volume18,669 shsAverage Volume50,526 shsMarket Capitalization$27.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. Read More Receive RNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rein Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RNTX Stock News HeadlinesRein Therapeutics (NASDAQ:RNTX) Cut to "Hold" at Brookline Capital ManagementAugust 21 at 2:29 AM | americanbankingnews.comBrookline Capital Downgrades Rein Therapeutics (RNTX)August 19 at 11:47 PM | msn.comSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinking and demand surging from AI, EVs, and defense tech, this could be the most overlooked setup of 2025. Most investors haven’t caught on yet.August 22 at 2:00 AM | GoldenCrest Metals (Ad)Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trialAugust 19 at 1:44 PM | msn.comRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisAugust 19 at 8:00 AM | globenewswire.comRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025August 14, 2025 | globenewswire.comXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7, 2025 | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comSee More Headlines RNTX Stock Analysis - Frequently Asked Questions How have RNTX shares performed this year? Rein Therapeutics' stock was trading at $2.05 at the beginning of the year. Since then, RNTX shares have decreased by 41.8% and is now trading at $1.1924. How were Rein Therapeutics' earnings last quarter? Rein Therapeutics Inc. (NASDAQ:RNTX) released its earnings results on Thursday, August, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.06. Who are Rein Therapeutics' major shareholders? Top institutional shareholders of Rein Therapeutics include BIOS Capital Management LP (7.34%), Voss Capital LP (6.22%), University of Texas Texas AM Investment Management Co. (2.31%) and Cable Car Capital LP (1.82%). How do I buy shares of Rein Therapeutics? Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNTX CIK1420565 WebN/A Phone(737) 802-1989FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.11% Return on Assets-33.83% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio1.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.46 per share Price / Cash Flow2.57 Book Value$0.13 per share Price / Book9.17Miscellaneous Outstanding Shares23,310,000Free Float22,116,000Market Cap$27.79 million OptionableN/A Beta1.31 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RNTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.